EZH2 and non-Hodgkin lymphoma: Gain-of-function mutations that constitutively activate EZH2 (especially missense mutations of tyrosine 641) are highly prevalent in non–Hodgkin lymphoma–type (NHL-type) B cell lymphomas of germinal center origin (13), and tazemetostat was specifically indicated for adult patients with FL with an identified EZH2 mutation based on clinical trial results.